Abstract: There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGF? superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and/or cardiometabolic disease, bone damage, and/or low red blood cell levels (such as anemia).

Abstract: There are provided tetravalent TGF? receptor-ectodomain based traps having a tailored isoform-specificity profile for neutralization of TGF? ligands, and methods of use thereof in the treatment of diseases and conditions associated with TGF?, particularly TGF?1 and TGF?3. In particular, there are provided TGF? binding agents designed to tailor TGF? isoform specificity, in order to maximize therapeutic efficacy in specific disease indications while minimizing adverse effects. The TGF? binding agents comprise two polypeptides assembled via a multimerization domain, each polypeptide having two TGF?II receptor (TGF?R) ligand-binding domains linked as a doublet, wherein the linkers are selected to tailor isoform specificity.

Abstract: There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGF? superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and/or cardiometabolic disease, bone damage, and/or low red blood cell levels (such as anemia).

Abstract: The present invention provides methods and compositions to reduce binding of fibrinogen to the ClfA in a gram positive bacterial infections using monoclonal antibody, a polyclonal antibody, an antigen-binding antibody fragment or a composition that specifically binds to a portion of ClfA with the sequence of SEQ ID No: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.

Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.

Abstract: The present invention provides methods and compositions to reduce binding of fibrinogen to the ClfA in a gram positive bacterial infections using monoclonal antibody, a polyclonal antibody, an antigen-binding antibody fragment or a composition that specifically binds to a portion of ClfA with the sequence of SEQ ID No: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.

Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.

Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.

Abstract: The present invention provides a method for determining the structure of a microbial surface components recognizing adhesive matrix molecule in complex with fibrinogen, by providing a ClfA complexed with a fibrinogen gamma-peptide; determining a ClfA binding region of the fibrinogen gamma-peptide; determining one or more critical amino acid residues in the ClfA binding region of a native fibrinogen gamma-peptide that is critical for a ClfA:fibrinogen gamma-peptide interaction; determining one or more amino acid residues of the ClfA that binds to the ClfA binding region of the native fibrinogen gamma-peptide; modeling the structure of the ClfA binding region; determining the structure of the ClfA in complex with the :fibrinogen gamma-peptide interaction; and identifying one or more potential agent(s) that inhibit the ClfA:fibrinogen gamma-peptide interaction without affecting binding of other proteins to the fibrinogen gamma-peptide.

Abstract: The present invention describes the design and development of new fibrinogen and fibrinogen derived products with significantly reduced binding to bacteria while retaining normal physiological functions by using modified fibrinogen amino acid sequences. The present invention describes modified sequences of Fg ?-chains and ?-chains with reduced binding to S. aureus ClfA and S. epidermidis SdrG respectively. Modified Fg with the described modifications will not bind other bacterial surface proteins that bind Fg using similar mechanisms as ClfA and SdrG. These new Fg and Fg derived products will therefore have less binding to bacteria and will be advantageous compared to normal human Fg in a number of different settings.